{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:29:16Z","timestamp":1780050556382,"version":"3.53.1"},"reference-count":65,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100007721","name":"Cure SMA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007721","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>\u00a0<\/jats:title>\n                  <jats:p>Disease-modifying therapies for spinal muscular atrophy (SMA) are rapidly changing the outlook for many individuals by substantially altering the clinical course, phenotypic expression, and functional outcomes. Physical therapists have played critical roles in the effective conduct and execution of clinical trials leading to the approval of these therapies. Given the treatment landscape, educating practicing clinicians to understand best practice is of great importance, and a timely call to action to facilitate knowledge translation from SMA researchers to clinicians is necessary. The SMA Clinical Trial Readiness Program engaged clinical and research centers, identified physical therapy knowledge gaps related to evaluation and outcomes assessment, and provided educational resources, including the development of a SMA Best Practices Clinical Evaluator Toolkit. Toolkit content synthesizes evidence and covers a breadth of issues relevant to practice, including background on SMA and the drug pipeline; therapist roles and responsibilities related to research; clinical and research evaluation; and useful materials and resources for additional education, training, and professional development. Surveys and telephone interviews were conducted with physical therapists managing individuals with SMA to determine their SMA practice experience and educational needs. Their recommendations, along with synthesized SMA research evidence, provided input into toolkit content development and assisted in identifying gaps important to address. Impact was assessed over time via utilization feedback surveys downloaded by clinicians across various settings. Open-ended feedback supported beneficial use of the toolkit for clinicians and researchers working with individuals with SMA. Next steps should include timely dissemination to bring this resource and others into practice in a systematic, efficacious, and engaging manner. As the treatment landscape for SMA evolves, the therapist\u2019s role in multidisciplinary care and research is of great importance, and a call to action for the development, implementation, evaluation and reporting of informed knowledge using evidence-based knowledge translation strategies is critical.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Impact<\/jats:title>\n                  <jats:p>Partnership among patient advocacy groups, industry collaborators, and key opinion leaders\/experts can optimize essential resource development to address the knowledge gap for best practices in physical therapy. This partnership model can be replicated for other diseases, providing an efficient way to support clinical trial readiness and target early development of evidence-based content and resources related to both research and best practice clinical evaluation for physical therapist researchers, clinicians, and patients. While identifying knowledge gaps and resource development are initial steps toward change in SMA practice, a rapidly changing rehabilitation outlook warrants a call to action for enhanced efforts aimed at improving rehabilitation evaluation, assessment, and care for this population. It is critical to forge a timely path forward for development, implementation, and sustainability of effective knowledge translation to practice for SMA.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ptj\/pzac108","type":"journal-article","created":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T14:09:41Z","timestamp":1659103781000},"source":"Crossref","is-referenced-by-count":12,"title":["Clinical and Research Readiness for Spinal Muscular Atrophy: The Time Is Now for Knowledge Translation"],"prefix":"10.1093","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2879-5055","authenticated-orcid":false,"given":"Kristin J","family":"Krosschell","sequence":"first","affiliation":[{"name":"Northwestern University Department of Physical Therapy and Human Movement Sciences, Feinberg School of Medicine, , Chicago, Illinois , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Dunaway Young","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine Department of Neurology, , Stanford, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse","family":"Peterson","sequence":"additional","affiliation":[{"name":"Faegre Drinker Biddle and Reath LLP , Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Curry","sequence":"additional","affiliation":[{"name":"Cure SMA, Elk Grove Village , Illinois , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Mazzella","sequence":"additional","affiliation":[{"name":"Cure SMA, Elk Grove Village , Illinois , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Jarecki","sequence":"additional","affiliation":[{"name":"Cure SMA, Elk Grove Village , Illinois , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ros\u00e1ngel","family":"Cruz","sequence":"additional","affiliation":[{"name":"Cure SMA, Elk Grove Village , Illinois , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,7,29]]},"reference":[{"key":"2022103118013942400_ref1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ejhg.2011.134","article-title":"Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of &gt;72,400 specimens","volume":"20","author":"Sugarman","year":"2012","journal-title":"Eur J Hum Genet"},{"key":"2022103118013942400_ref2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"2022103118013942400_ref3","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","article-title":"Spinal muscular atrophy","volume":"33","author":"Kolb","year":"2015","journal-title":"Neurol Clin"},{"key":"2022103118013942400_ref4","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.24497","article-title":"Spinal muscular atrophy: diagnosis and management in a new therapeutic era","volume":"51","author":"Arnold","year":"2015","journal-title":"Muscle Nerve"},{"key":"2022103118013942400_ref5","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/jnnp-2016-314292","article-title":"Association of motor milestones, SMN2 copy and outcome in spinal muscular atrophy types 0-4","volume":"88","author":"Wadman","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2022103118013942400_ref6","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1172\/JCI121658","article-title":"Two breakthrough gene-targeted treatments for spinal muscular atrophy: challenges remain","volume":"128","author":"Sumner","year":"2018","journal-title":"J Clin Invest"},{"key":"2022103118013942400_ref7","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/14656566.2019.1704732","article-title":"New treatments in spinal muscular atrophy: an overview of currently available data","volume":"21","author":"Ramdas","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"2022103118013942400_ref8","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"key":"2022103118013942400_ref9","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham Control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"key":"2022103118013942400_ref10","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus Sham Control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"key":"2022103118013942400_ref11","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"2022103118013942400_ref12","doi-asserted-by":"crossref","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","article-title":"Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1\/2 studies","volume":"92","author":"Darras","year":"2019","journal-title":"Neurology"},{"key":"2022103118013942400_ref13","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2147\/TCRM.S172291","article-title":"Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives","volume":"15","author":"Dangouloff","year":"2019","journal-title":"Ther Clin Risk Manag"},{"key":"2022103118013942400_ref14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JND-190424","article-title":"Advances in treatment of spinal muscular atrophy - new phenotypes, new challenges, new implications for care","volume":"7","author":"Schorling","year":"2020","journal-title":"J Neuromuscul Dis"},{"key":"2022103118013942400_ref15","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"key":"2022103118013942400_ref16","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"2022103118013942400_ref17","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3233\/JND-180327","article-title":"Motor function test reliability during the neuronext spinal muscular atrophy infant biomarker study","volume":"5","author":"Krosschell","year":"2018","journal-title":"J Neuromuscul Dis"},{"key":"2022103118013942400_ref18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3233\/JND-180301","article-title":"Evaluator training and reliability for SMA global Nusinersen trials1","volume":"5","author":"Glanzman","year":"2018","journal-title":"J Neuromuscul Dis"},{"key":"2022103118013942400_ref19","volume-title":"Common data elements: spinal muscular atrophy","author":"National Institute of Neurological Disorders and Stroke","year":"2020"},{"key":"2022103118013942400_ref20","volume-title":"NINDS common data elements: neuromuscular diseases","author":"National Institute of Neurological Disorders and Stroke","year":"2020"},{"key":"2022103118013942400_ref21","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1177\/0883073807305788","article-title":"Consensus statement for standard of care in spinal muscular atrophy","volume":"22","author":"Wang","year":"2007","journal-title":"J Child Neurol"},{"key":"2022103118013942400_ref22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0249279","article-title":"Essential competencies for physical therapist managing individuals with spinal muscular atrophy: a delphi study","volume":"16","author":"Timmerberg","year":"2021","journal-title":"PLoS One"},{"key":"2022103118013942400_ref23","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1212\/WNL.0b013e318271f7e4","article-title":"Prospective cohort study of spinal muscular atrophy types 2 and 3","volume":"79","author":"Kaufmann","year":"2012","journal-title":"Neurology"},{"key":"2022103118013942400_ref24","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","author":"Finkel","year":"2014","journal-title":"Neurology"},{"key":"2022103118013942400_ref25","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.nmd.2015.10.006","article-title":"Patterns of disease progression in type 2 and 3 SMA: implications for clinical trials","volume":"26","author":"Mercuri","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"2022103118013942400_ref26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199657","article-title":"Ambulatory function in spinal muscular atrophy: age-related patterns of progression","volume":"13","author":"Montes","year":"2018","journal-title":"PLoS One"},{"key":"2022103118013942400_ref27","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.nmd.2019.10.001","article-title":"A critical review of patient and parent caregiver oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in spinal muscular atrophy","volume":"29","author":"Messina","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"2022103118013942400_ref28","volume-title":"Best Practices for physical therapists and clinical Evaluators in Spinal Muscular Atrophy (SMA): recommendations to support the effective conduct of clinical trials in SMA","author":"Krosschell"},{"key":"2022103118013942400_ref29","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1212\/WNL.0b013e3181d3e308","article-title":"Six-Minute Walk Test demonstrates motor fatigue in spinal muscular atrophy","volume":"74","author":"Montes","year":"2010","journal-title":"Neurology"},{"key":"2022103118013942400_ref30","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/mus.21917","article-title":"Fatigue leads to gait changes in spinal muscular atrophy","volume":"43","author":"Montes","year":"2011","journal-title":"Muscle Nerve"},{"key":"2022103118013942400_ref31","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/mus.24081","article-title":"Leg muscle function and fatigue during walking in spinal muscular atrophy type 3","volume":"50","author":"Montes","year":"2014","journal-title":"Muscle Nerve"},{"key":"2022103118013942400_ref32","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12883-017-0790-9","article-title":"Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy","volume":"17","author":"Pera","year":"2017","journal-title":"BMC Neurol"},{"key":"2022103118013942400_ref33","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/mus.26419","article-title":"Revised upper limb module for spinal muscular atrophy: 12 month changes","volume":"59","author":"Pera","year":"2019","journal-title":"Muscle Nerve"},{"key":"2022103118013942400_ref34","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.nmd.2020.07.004","article-title":"Gain and loss of abilities in type II SMA: a 12-month natural history study","volume":"30","author":"Coratti","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"2022103118013942400_ref35","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.nmd.2020.07.005","article-title":"Age and baseline values predict 12 and 24-month functional changes in type 2 SMA","volume":"30","author":"Coratti","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"2022103118013942400_ref36","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1111\/ene.14472","article-title":"Minimal clinically important differences in functional motor scores in adults with spinal muscular atrophy","volume":"27","author":"Stolte","year":"2020","journal-title":"Eur J Neurol"},{"key":"2022103118013942400_ref37","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/mus.25120","article-title":"Six-minute walk test is reliable and valid in spinal muscular atrophy","volume":"54","author":"Dunaway Young","year":"2016","journal-title":"Muscle Nerve"},{"key":"2022103118013942400_ref38","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.nmd.2017.07.007","article-title":"6MWT can identify type 3 SMA patients with neuromuscular junction dysfunction","volume":"27","author":"Pera","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"2022103118013942400_ref39","article-title":"The Development and standardization of an intensive inpatient rehabilitation program in patients with spinal muscular atrophy receiving nusinersen treatment","author":"Carruth","year":"2020","journal-title":"Cure SMA Virtual Research Poster Meeting"},{"key":"2022103118013942400_ref40","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.nmd.2021.02.011","article-title":"Filling the gaps in knowledge translation: physical therapy recommendations for individuals with spinal muscular atrophy compared to standard of care guidelines","volume":"31","author":"Trenkle","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"2022103118013942400_ref41","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5734\/JGM.2020.17.2.55","article-title":"Rehabilitation of spinal muscular atrophy: current consensus and future direction","volume":"17","author":"Yi","year":"2020","journal-title":"J Gene Med"},{"key":"2022103118013942400_ref42","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13023-020-01387-8","article-title":"The SMA Clinical Trial Readiness Program: creation and evaluation of a program to enhance SMA trial readiness in the United States","volume":"15","author":"Peterson","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"2022103118013942400_ref43","doi-asserted-by":"crossref","first-page":"486","DOI":"10.2522\/ptj.2015.95.4.486","article-title":"Knowing is not enough; we must apply. Willing is not enough; we must do","volume":"95","author":"Li","year":"2015","journal-title":"Phys Ther"},{"key":"2022103118013942400_ref44","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0140-6736(03)14546-1","article-title":"From best evidence to practice: effective implementation of change in patients\u2019 care","volume":"362","author":"Grol","year":"2003","journal-title":"Lancet"},{"key":"2022103118013942400_ref45","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1748-5908-7-50","article-title":"Knowledge translation of research finfings","volume":"7","author":"Grimshaw","year":"2012","journal-title":"Implement Sci"},{"key":"2022103118013942400_ref46","doi-asserted-by":"crossref","first-page":"648","DOI":"10.2522\/ptj.20130500","article-title":"Best practice recommendations for the development, implementation, and evaluation of online knowledge translation resources in rehabilitation","volume":"95","author":"Levac","year":"2015","journal-title":"Phys Ther"},{"key":"2022103118013942400_ref47","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/acn3.283","article-title":"Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study","volume":"3","author":"Kolb","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"2022103118013942400_ref48","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.conctc.2018.07.002","article-title":"Recruitment and retention program for the NeuroNEXT SMA Biomarker Study: Super Babies for SMA!","volume":"11","author":"Bartlett","year":"2018","journal-title":"Contemp Clin Trials Commun"},{"key":"2022103118013942400_ref49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035462","article-title":"Candidate proteins, metabolites and transcripts in the Biomarkers for Spinal Muscular Atrophy (BforSMA) clinical study","volume":"7","author":"Finkel","year":"2012","journal-title":"PLoS One"},{"key":"2022103118013942400_ref50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033572","article-title":"Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study","volume":"7","author":"Crawford","year":"2012","journal-title":"PLoS One"},{"key":"2022103118013942400_ref51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060113","article-title":"SMA-MAP: a plasma protein panel for spinal muscular atrophy","volume":"8","author":"Kobayashi","year":"2013","journal-title":"PLoS One"},{"key":"2022103118013942400_ref52","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ppul.24203","article-title":"Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy","volume":"54","author":"Al-Zaidy","year":"2019","journal-title":"Pediatr Pulmonol"},{"key":"2022103118013942400_ref53","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/nat.2017.0665","article-title":"FDA approval of Nusinersen for spinal muscular atrophy makes 2016 the year of splice modulating oligonucleotides","volume":"27","author":"Aartsma-Rus","year":"2017","journal-title":"Nucleic Acid Ther"},{"key":"2022103118013942400_ref54","article-title":"Nusinersen treatment of spinal muscular atrophy\u2014a systematic review","volume":"67","author":"Albrechtsen","year":"2020","journal-title":"Dan Med J"},{"key":"2022103118013942400_ref55","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJMoa2009965","article-title":"Risdiplam in Type 1 spinal muscular atrophy","volume":"384","author":"Baranello","year":"2021","journal-title":"N Engl J Med"},{"key":"2022103118013942400_ref56","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s40265-020-01410-z","article-title":"Risdiplam: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"2022103118013942400_ref57","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s13311-020-01004-3","article-title":"Reldesemtiv in patients with spinal muscular atrophy: a phase 2 hypothesis-generating study","volume":"18","author":"Rudnicki","year":"2021","journal-title":"Neurotherapeutics"},{"key":"2022103118013942400_ref58","volume-title":"MDA Clinical and Scientific Conference 2021","author":"Place"},{"key":"2022103118013942400_ref59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012140","article-title":"SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy","volume":"5","author":"Swoboda","year":"2010","journal-title":"PLoS One"},{"key":"2022103118013942400_ref60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021296","article-title":"SMA CARNIVAL TRIAL PART II: a prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy","volume":"6","author":"Kissel","year":"2011","journal-title":"PLoS One"},{"key":"2022103118013942400_ref61","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/mus.25776","article-title":"Clinical trial of L-carnitine and valproic acid in spinal muscular atrophy type I","volume":"57","author":"Krosschell","year":"2018","journal-title":"Muscle Nerve"},{"key":"2022103118013942400_ref62","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/mus.23904","article-title":"SMA valiant trial: a prospective, double-blind, placebo-controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy","volume":"49","author":"Kissel","year":"2014","journal-title":"Muscle Nerve"},{"key":"2022103118013942400_ref63","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3233\/JND-140004","article-title":"A randomized, controlled clinical trial of exercise in patients with spinal muscular atrophy: methods and baseline characteristics","volume":"1","author":"Montes","year":"2014","journal-title":"J Neuromuscul Dis"},{"key":"2022103118013942400_ref64","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3233\/JND-150101","article-title":"Single-blind, randomized, controlled clinical trial of exercise in ambulatory spinal muscular atrophy: why are the results negative?","volume":"2","author":"Montes","year":"2015","journal-title":"J Neuromuscul Dis"},{"key":"2022103118013942400_ref65","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/mus.24568","article-title":"Resistance strength training exercise in children with spinal muscular atrophy","volume":"52","author":"Lewelt","year":"2015","journal-title":"Muscle Nerve"}],"container-title":["Physical Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ptj\/advance-article-pdf\/doi\/10.1093\/ptj\/pzac108\/45187139\/pzac108.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ptj\/article-pdf\/102\/10\/pzac108\/46699124\/pzac108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ptj\/article-pdf\/102\/10\/pzac108\/46699124\/pzac108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T18:03:18Z","timestamp":1667239398000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ptj\/article\/doi\/10.1093\/ptj\/pzac108\/6651754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,29]]},"references-count":65,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10,6]]}},"URL":"https:\/\/doi.org\/10.1093\/ptj\/pzac108","relation":{},"ISSN":["0031-9023","1538-6724"],"issn-type":[{"value":"0031-9023","type":"print"},{"value":"1538-6724","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10,1]]},"published":{"date-parts":[[2022,7,29]]},"article-number":"pzac108"}}